Statement by William G. Bowen, Chairman of the Special Committee of Merck & Co., Inc. ( PDF* 8KB)

Merck & Co., Inc. Statement regarding the Martin Report ( PDF* 47KB)

Introduction ( PDF* 140KB)

Our Findings ( PDF* 1MB)

Conclusion ( PDF* 28KB)

• Exhibit 1 - Merck Leadership and Organizational Structure ( PDF* 227KB)
  
  
• Exhibit 2 - Alphabetical List of Witnesses Interviewed ( PDF* 369KB)
  
  
• Exhibit 3 - Statistical Significance ( PDF* 187KB)
  
  
• Exhibit 4 - Glossary of Terms ( PDF* 282KB)
  
  
• Exhibit 5 - Timeline of Epidemiological Studies Cited in Appendix P ( PDF* 1MB)
  
  

Appendices and Timelines
Appendix A - Development of Vioxx (Sections A-G) ( PDF* 750KB)

Appendix A - Development of Vioxx (Sections H-L) ( PDF* 647KB)

• Appendix A - Timeline ( PDF* 331KB)
  
  

Appendix B - Pre-Approval Commercial Context ( PDF* 770KB)

Appendix C - Merck's New Drug Application for Approval to Market Vioxx ( PDF* 282KB)

• Appendix C - Timeline ( PDF* 127KB)
  
  

Appendix D – The VIGOR Trial ( PDF* 600KB)

• Appendix D – Timeline ( PDF* 302KB)
  
  

Appendix E – Merck’s Interpretation of and Response to VIGOR Trial Cardiovascular Data: March 9-27, 2000 ( PDF* 928KB)

• Appendix E – Timeline ( PDF* 120KB)
  
  

Appendix F – Further Analysis and Public Presentation of VIGOR Trial Cardiovascular Data: April 2000 – January 2001 ( PDF* 931KB)

• Appendix F – Timeline ( PDF* 351KB)
  
  

Appendix G – Communication of Vioxx Cardiovascular Safety Data to Physicians ( PDF* 573KB)

• Appendix G – Timeline ( PDF* 228KB)
  
  

Appendix H – Criticism of Vioxx’s Renal Safety Profile ( PDF* 221KB)

• Appendix H – Timeline ( PDF* 262KB)
  
  

Appendix I – Merck’s Supplemental New Drug Application and Initial FDA Review ( PDF* 1MB)

• Appendix I – Timeline ( PDF* 328KB)
  
  

Appendix J – Further Analysis of the Cardiovascular Safety Profile of Vioxx: Post-February 2001 ( PDF* 504KB)

• Appendix J – Timeline ( PDF* 260KB)
  
  

Appendix K – Advocate Development ( PDF* 908KB)

• Appendix K – Timeline ( PDF* 226KB)
  
  

Appendix L – Combination Therapies Considered ( PDF* 430KB)

• Appendix L – Timeline ( PDF* 347KB)
  
  

Appendix M – Post-VIGOR Efforts to Develop and Evaluate Additional Vioxx-Related Cardiovascular Data ( PDF* 611KB)

• Appendix M – Timeline ( PDF* 304KB)
  
  

Appendix N – FDA Analysis of Vioxx Cardiovascular Data and Label Issues ( PDF* 1MB)

• Appendix N – Timeline ( PDF* 438KB)
  
  

Appendix O – Communications with the FDA Apart from Label Negotiations ( PDF* 1MB)

Appendix P – Additional Studies Relevant to Cardiovascular Safety of Selective Cox-2 Inhibitors ( PDF* 1MB)

• Appendix P – Timeline ( PDF* 438KB)
  
  

Appendix Q – APPROVe Trial Cardiovascular Data and Withdrawal of Vioxx ( PDF* 707KB)

• Appendix Q – Timeline ( PDF* 376KB)
  
  

Appendix R – Post-Withdrawal Analyses and Reporting of Cardiovascular Data Arising from the APPROVe Trial (Section A) ( PDF* 278KB)

Appendix R – Post-Withdrawal Analyses and Reporting of Cardiovascular Data Arising from the APPROVe Trial (Section B) ( PDF* 1.2MB)

Appendix R – Post-Withdrawal Analyses and Reporting of Cardiovascular Data Arising from the APPROVe Trial (Sections C-D) ( PDF* 889KB)

• Appendix R – Timeline ( PDF* 513KB)
  
  

Appendix S – Merck’s Compensation and Securities Trading Policies ( PDF* 471KB)

Appendix T – Board Awareness of Vioxx’s Cardiovascular Safety Profile and Involvement in Vioxx Development and Marketing ( PDF* 296KB)